Is a complete DMRA research report available?

No complete published report is available for Damora Therapeutics, Inc. (DMRA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Damora Therapeutics, Inc. (DMRA)

NASDAQ: DMRA · USD

$28.3

-1.09 (-3.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first DMRA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1.7B
Net income (ttm)	-235.1M
EPS (ttm)	-$24.5
Shares out	61.6M
Volume	323,117
Beta	1.47
Price target	$43.4	+53.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -235.1M
EPS (ttm): -$24.5
Market cap: 1.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All DMRA indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001800315
Company name	Damora Therapeutics, Inc.
Country	United States
Country code	US
Cusip	G2646Y104
Employees	7
Employees Change	2%
Employees Change Percent	40
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-10-29
Isin	KYG2646Y1044
Last refreshed	2026-07-30
Market cap	$1.7B
Market cap category	Small-Cap
Price	$28.33
Price currency	USD
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Sic	2834
Symbol	DMRA
Website	https://www.damoratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.48%
FCF yield	-1.43%
P/B ratio	4.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-235.1M
Net Income Growth Years	0%
Profit Per Employee	$-33.6M
ROA	-14.7
Roa5y	-31.38
ROCE	-46.73
ROE	-89.5
Roe5y	-87.97
ROIC	-15.41

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	652.5%
Cagr3y	-27.87%
Cagr5y	-23.97%
EPS Growth Quarters	13
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$535.4M
Cash	$532.9M
Current Assets	$535.4M
Current Liabilities	$23.8M
Debt	$0
Equity	$511.6M
Liabilities	$23.8M
Long Term Assets	$34,000
Long Term Liabilities	$27,000
Net Cash	$532.9M
Net Cash By Market Cap	$30.56
Net Cash Growth	4,390.97%
Net Debt Equity	$-1.04
Tangible Book Value	$379.2M
Tangible Book Value Per Share	$6.29
WACC	12.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	22.48
Net Working Capital	$-21.3M
Quick ratio	22.42
Working Capital	$511.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-689.73%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	651.46%
200-day SMA	23.6
3Y total return	-62.48%
50-day SMA	25.77
50-day SMA vs 200-day SMA	50over200
5Y total return	-74.59%
All Time High	449.8
All Time High Change	-93.7%
All Time High Date	2020-11-23
All Time Low	2.01
All Time Low Change	1,309.45%
All Time Low Date	2025-04-09
ATR	2.46
Beta	1.47
Beta1y	-4.13
Beta2y	0.17
Ch YTD	23.12
High	30.05
High52	38.33
High52 Date	2025-12-26
High52ch	-26.08%
Low	28.16
Low52	2.45
Low52 Date	2025-09-09
Low52ch	1,056.33%
Ma50ch	9.93%
Premarket Change Percent	-2.79
Premarket Price	$28.6
Price vs 200-day SMA	20.05%
RSI	49.96
RSI Monthly	55.06
RSI Weekly	56.11
Sharpe ratio	1.34x
Sortino ratio	7.65
Total Return	-689.73%
Tr YTD	23.12
Tr1m	11.71%
Tr1w	-5.54%
Tr3m	16.92%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	9
Analyst Price Target Top	$44
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.37
Operating Income	$-64.8M
Price target	$43.38
Price Target Change	$53.12
Price Target Change Top	$55.31

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,216,855%
Float Percent	66.96%
Shares Insiders	0.24%
Shares Institutions	70.47%
Shares Out	61,553,194
Shares Qo Q	2,216.95%
Shares Yo Y	689.73%
Short Float	11.37%
Short Ratio	4.84
Short Shares	7.62

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-28.8M
Adjusted OCF	-28,848,000
Average Volume	518,129.15x
Bv Per Share	6.29
Ch1m	11.71
Ch1w	-5.54
Ch1y	651.5
Ch3m	16.92
Ch3y	-62.48
Ch5y	-74.59
Ch6m	15.87
Change	-3.7%
Change From Open	-3.7
Close	29.42
Days Gap	0
Depreciation Amortization	22,000
Dollar Volume	9,153,904.6
Earnings Date	2026-08-03
Earnings Time	amc
EBIT	$-239.1M
EBITDA	$-239M
EPS	$-24.47
F Score	2
FCF	$-24.9M
FCF EV Yield	-2.06x
FCF Per Share	$-0.4
Financing CF	562,765,000
Fiscal Year End	December
Founded	2,011
Income Tax	$90,000
Investing CF	-17,374,000
Iprfo	-92.45
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2024-08-30
Last Split Type	Reverse
Last10k Filing Date	2026-03-19
Ma150	25.75
Ma150ch	10.02%
Ma20	29.83
Ma20ch	-5.02%
Net CF	520,960,000
Next Earnings Date	2026-08-11
Open	29.42
Optionable	No
Position In Range	8.99
Post Close	28.33
Postmarket Change Percent	-1.94
Postmarket Price	$27.78
Pre Close	29.42
Price Date	2026-07-29
Ptbv Ratio	4.6
Relative Volume	0.62x
Share Based Comp	3,963,000
Tr6m	15.87%
Us State	Massachusetts
Volume	323,117

Damora Therapeutics, Inc. (DMRA)

Coverage state: Market snapshot only — no published research

Generate the first DMRA analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · DMRA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DMRA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on DMRA

Frequently asked questions